# Thryv Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/thryv-therapeutics

- Industry: Biotechnology
- Headquarters: Montreal, Canada
- Website: www.thryvtrx.com
- Total disclosed funding: $49M
- Latest round: Series B (Nov 5, 2026)
- Investors on record: 12

## About

Based in Montreal, Canada and founded in 2019, Thryv Therapeutics Inc. develops medicines for to treat long QT syndrome, heart failure, and atrial fibrillation with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase.

## Funding rounds

- Series B, Nov 5, 2026, $30M — Inc., InClin, Amplitude Ventures, CTI Life Sciences Fund, Fonds de solidarité FTQ, Investissement Québec, adMare BioInnovations, Lumira Ventures, Alexandria Venture Investments
- Series A, Aug 10, 2021, $19M — Alexandria Venture Investments, Amplitude, Fonds de solidarite FTQ, Amzak Capital Management, Lumira Ventures

## Investors

- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A, Series B
- Amplitude (https://capitalatlas.ai/funds/amplitude) — Series A
- Fonds de solidarite FTQ (https://capitalatlas.ai/funds/fonds-de-solidarite-ftq) — Series A
- Amzak Capital Management (https://capitalatlas.ai/funds/amzak-capital-management) — Series A
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series A, Series B
- Inc. — Series B
- InClin — Series B
- Amplitude Ventures — Series B
- CTI Life Sciences Fund — Series B
- Fonds de solidarité FTQ — Series B
- Investissement Québec — Series B
- adMare BioInnovations (https://capitalatlas.ai/funds/admare-bioinnovations) — Series B